使用靶向造血干细胞的脂质纳米颗粒构建致死性α-地中海贫血小鼠模型并通过慢病毒基因治疗
研究利用靶向CD117的脂质纳米颗粒递送Cre mRNA,在体外高效敲除造血干细胞中的α-珠蛋白基因,移植后小鼠出现HbH合成、红系造血异常及器官形态异常,约8周后致死。携带至少1拷贝表达α-珠蛋白的慢病毒载体ALS20αI的小鼠可长期存活,红系造血正常化、HbH减少、器官形态改善。在患者来源的CD34+细胞中,ALS20αI改善α/β-珠蛋白mRNA比值并减少HbH形成。
要点
- 靶向CD117的脂质纳米颗粒可高效在体外敲除造血干细胞中的α-珠蛋白基因。
- 移植敲除α-珠蛋白的造血干细胞后,小鼠出现HbH、红系造血异常及器官形态异常,约8周致死。
- 携带ALS20αI的小鼠长期存活,红系造血正常化、HbH减少、器官形态改善。
核心结论
- 研究证明脂质纳米颗粒可用于疾病建模,并表征了一种新的严重α-地中海贫血小鼠模型,以及ALS20αI治疗α-地中海贫血的疗效。
研究设计与样本
- 研究使用靶向CD117的脂质纳米颗粒递送Cre mRNA(mRNACreLNPCD117),在体外处理造血干细胞以敲除floxed α-珠蛋白基因,并将这些细胞移植到清髓小鼠中,比较有无ALS20αI的情况。
主要发现
- 移植经mRNACreLNPCD117处理的造血干细胞的小鼠显示α-珠蛋白基因完全敲除,表现为HbH(β-四聚体或β4)合成、红系造血异常和器官形态异常,移植后约8周致死。
- 移植经mRNACreLNPCD117处理且携带至少1拷贝ALS20αI的造血干细胞的小鼠长期存活,红系造血正常化、HbH生成减少、器官形态异常改善。
- 在来自α-珠蛋白敲除的CD34+细胞以及来自缺失型和非缺失型HbH病患者的红系祖细胞中测试ALS20αI,显示α-珠蛋白/β-珠蛋白mRNA比值改善,高效液相色谱显示HbH形成减少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
α-Thalassemia (AT) is one of the most commonly occurring inherited hematological diseases. However, few treatments are available, and allogeneic bone marrow transplantation is the only available therapeutic option for patients with severe AT. Research into AT has remained limited because of a lack of adult mouse models, with severe AT typically resulting in in utero lethality. By using a lipid nanoparticle (LNP) targeting the receptor CD117 and delivering a Cre messenger RNA (mRNACreLNPCD117), we were able to delete floxed α-globin genes at high efficiency in hematopoietic stem cells (HSC) ex vivo. These cells were then engrafted in the absence or presence of a novel α-globin-expressing lentiviral vector (ALS20αI). Myeloablated mice infused with mRNACreLNPCD117-treated HSC showed a complete knock out (KO) of α-globin genes. They showed a phenotype characterized by the synthesis of hemoglobin H (HbH; also known as β-tetramers or β4), aberrant erythropoiesis, and abnormal organ morphology, culminating in lethality ∼8 weeks after engraftment. Mice infused with mRNACreLNPCD117-treated HSC with at least 1 copy of ALS20αI survived long term with normalization of erythropoiesis, decreased production of HbH, and amelioration of the abnormal organ morphology. Furthermore, we tested ALS20αI in erythroid progenitors derived from α-globin-KO CD34+ cells and cells isolated from patients with both deletional and nondeletional HbH disease, demonstrating improvement in α-globin/β-globin mRNA ratio and reduction in the formation of HbH by high-performance liquid chromatography. Our results demonstrate the broad applicability of LNP for disease modeling, characterization of a novel mouse model of severe AT, and the efficacy of ALS20αI for treating AT.
引用
- Chappell ME, Breda L, Tricoli L, et al. Use of HSC-targeted LNP to generate a mouse model of lethal α-thalassemia and treatment via lentiviral gene therapy. Blood. 2024. PMID: 38949981. doi:10.1182/blood.2023023349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。